A Dedicated Amyloidosis Learning Pathway for the Nephrologist
The Amyloid Series synthesizes content from cardiology, nephrology, hematology, and hemodynamic physiology into a cohesive educational pathway. These five reviews are designed to be read in sequence, building from ATTR cardiac amyloidosis through monoclonal protein interpretation, echocardiographic pitfalls, hemodynamic assessment, and cardiac-predominant AL disease. Each module integrates evidence from landmark trials, clinical case data, and practical decision frameworks.
ATTRwt prevalence in HFpEF (10–15%), the preserved EF trap, PYP scintigraphy and the Gillmore algorithm, tafamidis/acoramidis/gene silencers, and the 13-month median diagnostic delay.
Comprehensive review
FLC reference ranges by eGFR (iStopMM), MASS-FIX panel structure, when to order SPEP vs immunofixation vs FLC, kappa vs lambda patterns, Mayo MGUS risk stratification, and SLiM criteria.
Comprehensive review
EF is a fraction not output, EF-CO dissociation with calculation examples, diastolic parameters (e’ velocity, E/e’), apical sparing strain, what echo cannot tell you, and when RHC is mandatory.
Comprehensive review
Restrictive physiology hemodynamic profile, Forrester classification, RA pressure and diuretic resistance, PCWP interpretation, and the restrictive vs constrictive vs HFpEF vs tamponade comparison.
Comprehensive review
20–30% of AL presents cardiac-predominant, lambda germline variants targeting myocardium, proteinuria phenotyping, cardiac vs hepatic ascites (SAAG framework), and FLC interpretation in CKD.
Comprehensive review
Andrew Bland, MD, MBA, MS
Medical Associates Department of Nephrology
University of Dubuque Physician Assistant Program | University of Illinois College of Medicine
© 2025–2026 Andrew Bland, MD. All rights reserved.
Clinical Mastery Series |
Urine Nephrology Now